Otarmeni (Lunsotogene Parvec-Cwha) Coverage Criteria
Customize your policy alerts
Sign up for Colorado Rocky Mountain Health Plans Policy 2026D0143A alerts
Get alerted when Policy 2026D0143A changes without checking for updates manually.
Monitor payer policy activity
Coverage and prior authorization for Otarmeni gene therapy in pediatric and adult patients with qualifying OTOF-related severe-to-profound or profound sensorineural hearing loss.
A new medical benefit drug policy was added establishing coverage criteria for Otarmeni.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.